NASDAQ
19.11.25 | 21:59
1,950 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | Shattuck Labs GAAP EPS of -$0.14 | 1 | Seeking Alpha | ||
| 06.11. | Shattuck Labs, Inc.: Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 106 | GlobeNewswire (Europe) | -First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers - - Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 - - Appointments... ► Artikel lesen | |
| 06.11. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | Shattuck Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.10. | Shattuck Labs stellt auf UEG-Kongress innovativen Ansatz zur IBD-Behandlung vor | 1 | Investing.com Deutsch | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 02.10. | Shattuck Labs, Inc.: Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel | 2 | GlobeNewswire (USA) | ||
| 26.08. | Shattuck Labs closes $103 million private placement led by OrbiMed | 2 | Investing.com | ||
| 26.08. | Shattuck Labs, Inc.: Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 26.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | H.C. Wainwright maintains Neutral rating on Shattuck Labs stock as FDA clears IND | 2 | Investing.com | ||
| 21.08. | Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease | 334 | GlobeNewswire (Europe) | - SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases - - The Company... ► Artikel lesen | |
| 14.08. | Leerink Partners senkt Kursziel für Shattuck Labs auf 2 $ | 1 | Investing.com Deutsch | ||
| 14.08. | Shattuck Labs stock price target lowered to $2 by Leerink Partners | 1 | Investing.com | ||
| 14.08. | Shattuck Labs GAAP EPS of -$0.24 in-line | 2 | Seeking Alpha | ||
| 14.08. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights | 122 | GlobeNewswire (Europe) | - Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 - - On track to dose first participant in... ► Artikel lesen | |
| 05.08. | Shattuck Labs stock soars after $103 million private placement | 4 | Investing.com | ||
| 05.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08. | Shattuck Labs, Inc.: Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million | 5 | GlobeNewswire (USA) |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUREXONE BIOLOGIC | 0,464 | +3,34 % | Breaking News: NurExone im Rennen um höchsten Biotech-Preis der Welt | ||
| ONCO-INNOVATIONS | 1,070 | +0,94 % | Onco-Innovations treibt die KI- und Quantencomputer-basierte Arzneimittelforschung durch die Zusammenarbeit mit Kuano voran, um die Entwicklung der PNKP-Inhibitor-Technologie zu beschleunigen | Vancouver, Kanada - 18. November 2025 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich bekannt zu geben,... ► Artikel lesen | |
| PRECIGEN | 3,806 | +4,05 % | Precigen, Inc.: Precigen Reports Third Quarter 2025 Financial Results and Business Updates | PAPZIMEOS (zopapogene imadenovec-drba) received full approval by the FDA in August
PAPZIMEOS launched with a broad label in the US as the first and only... ► Artikel lesen | |
| ALECTOR | 1,090 | +3,81 % | Alector Stock Plummets 63% in a Month: Here's What You Need to Know | ||
| KORRO BIO | 6,410 | 0,00 % | Korro Bio Early Trial Results Fall Short; Stock Hits New Low | ||
| FRACTYL HEALTH | 1,325 | 0,00 % | Fractyl Health outlines 2026 Revita pivotal data and PMA submission targets as clinical momentum accelerates | ||
| ALX ONCOLOGY | 1,480 | 0,00 % | Jefferies initiates coverage on ALX Oncology stock with Buy rating | ||
| QIAGEN | 38,070 | +0,83 % | Qiagen auf der Jefferies-Konferenz: Wachstumskurs trotz Herausforderungen | ||
| OLEMA PHARMACEUTICALS | 19,460 | 0,00 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| NUVATION BIO | 7,160 | 0,00 % | Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug | ||
| NUVALENT | 107,08 | +2,72 % | Nuvalent, Inc.: Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC | In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 82,14 | +5,58 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Third Quarter 2025 Financial Results | SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter... ► Artikel lesen | |
| BIONTECH | 88,00 | +0,06 % | BioNTech Aktie: Große Gewinne? - Bayer, Evotec, Hensoldt, Kontron und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,88 | +0,05 % | Avidity startet Programm für frühzeitigen Zugang zu DMD44-Therapie | ||
| ARCUTIS BIOTHERAPEUTICS | 27,900 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen |
Das Unternehmen SHATTUCK LABS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.